Enzalutamide

Red

Brand Name(s):Xtandi

Indication:Treatment of metastatic hormone-sensitive prostate cancer

Rationale:1,2

Considered:May-13

Review Date:Jul-26

Comments:
NICE TA712 recommend enzalutamide plus androgen deprivation therapy as an option for treating hormone-sensitive metastatic prostate cancer in adults.

Approval by MHRA of license extension for treatment of metastatic hormone-sensitive prostate cancer was based on results from Phase III ARCHES trial which showed use with androgen deprivation therapy (ADT) reduced risk of radiographic progression or death by 61% vs ADT alone.

NICE TA580
Enzalutamide for hormone-relapsed nonmetastatic
prostate cancer
May 2019